Tuesday, July 22, 2014

Mal-PEG-PLA/mPEG-PLA used for brain cancer therapy

PolySciTech (www.polyscitech.com) provides a wide array of maleimide-PEG-PLA and mPEG-PLA block copolymers for forming nanoparticles. Recently these types of polymers were used as precursors to generate paclitaxel loaded nanoparticles decorated with extra domain B aptamer for targeting towards glioma cells for brain cancer therapy. Read more: Gu, Guangzhi, Quanyin Hu, Xingye Feng, Xiaoling Gao, Jiang Menglin, Ting Kang, Di Jiang, Qingxiang Song, Hongzhuan Chen, and Jun Chen. "PEG-PLA nanoparticles modified with APT-EDB peptide for enhanced anti-angiogenic and anti-glioma therapy." Biomaterials (2014). http://www.sciencedirect.com/science/article/pii/S014296121400698X

“Abstract: Tumor neovasculature and tumor cells dual-targeting chemotherapy can not only destroy the tumor neovasculature, cut off the supply of nutrition and starve the tumor cells, but also directly kill tumor cells, holding great potential in overcoming the drawbacks of anti-angiogenic therapy only and improving the anti-glioma efficacy. In the present study, by taking advantage of the specific expression of fibronectin extra domain B (EDB) on both glioma neovasculature endothelial cells and glioma cells, we constructed EDB-targeted peptide APTEDB-modified PEG-PLA nanoparticles (APT-NP) for paclitaxel (PTX) loading to enable tumor neovasculature and tumor cells dual-targeting chemotherapy. PTX-loaded APT-NP showed satisfactory encapsulated efficiency, loading capacity and size distribution. In human umbilical vein endothelial cells, APT-NP exhibited significantly elevated cellular accumulation via energy-dependent, caveolae and lipid raft-involved endocytosis, and improved PTX-induced apoptosis therein. Both in vitro tube formation assay and in vivo matrigel angiogenesis analysis confirmed that APT-NP significantly improved the antiangiogenic ability of PTX. In U87MG cells, APT-NP showed elevated cellular internalization and also enhanced the cytotoxicity of the loaded PTX. Following intravenous administration, as shown by both in vivo live animal imaging and tissue distribution analysis, APT-NP achieved a much higher and specific accumulation within the glioma. As a result, APT-NP-PTX exhibited improved anti-glioma efficacy over unmodified nanoparticles and Taxol® in both subcutaneous and intracranial U87MG xenograft models. These findings collectively indicated that APTEDB-modified nanoparticles might serve as a promising nanocarrier for tumor cells and neovasculature dual-targeting chemotherapy and hold great potential in improving the efficacy anti-glioma therapy. Keywords: Nanoparticles; APTEDB peptide; Dual-targeting; Paclitaxel; Glioma therapy”
Post a Comment